Method
In order to investigate the in¯uence of PSA kinetics on the outcome of radiation therapy, PSA doubling time was calculated in patients with biochemical failure after radical prostatectomy; doubling time following delayedasalvage radiation therapy was also calculated in patients who underwent this treatment. Post-irradiation patients in whom PSA was undetectable by conventional assay were followed up using a hypersensitive PSA assay.
Results
Of the 125 patients who underwent radical prostatectomy for clinically resectable prostate cancer, 47 developed biochemical failure an average of 11.8 months after surgery. Thirty-eight underwent radiotherapy: 36 for isolated biochemical failure and two for local progression with elevated PSA levels. Mean PSA doubling time after surgery was 14.6 AE 16.2 months (n 42); after radiation therapy it was 13.3 AE 23.9 months (n 32). Eleven out of 30 evaluable patients (36.7%) had sustained PSA suppression lasting at least 12 months following radiotherapy. Only time to biochemical failure following surgery approached statistical signi®cance for predicting durable response to radiotherapy (P 0.08). The mean nadir value of PSA in the 11 patients with at least 12 months of sustained PSA suppression was 0.032 ngaml at 26.9 months.
Conclusion
The rapidity with which PSA levels double following surgery may provide a clinically signi®cant indication of the nature of these recurrent tumours. Slow-growing tumours with longer PSA doubling times may be better candidates for delayedasalvage radiation therapy. Larger studies involving more patients are needed to determine whether PSA doubling time can de®ne subgroups for which speci®c treatment strategies should be developed.
